Final answer:
Selling unapproved pharmaceuticals is a non-compliant business practice against FDA regulations designed to protect consumers. The strict regulatory process can inadvertently disadvantage pharmaceutical companies due to the time and expense involved, and patients who might lack access to new therapies.
Step-by-step explanation:
A decision to sell pharmaceuticals that have not been cleared with the Federal Drug Administration is an example of a non-compliant business practice. The Food and Drug Administration (FDA) rigorously regulates the medicines that pharmacies can sell in the United States to ensure they are safe and effective. This includes a thorough review process through a New Drug Application (NDA) for new drugs, which must be approved as safe and effective before they can be sold. Selling drugs without FDA approval can not only lead to legal consequences but can also pose significant health risks. Winners of strict medical regulations include consumers protected from harmful medications, whereas the losers may include companies facing long and costly approval processes, and patients who might miss out on potentially beneficial treatments that are delayed due to regulatory processes.